Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer
Myriad Genetics (NASDAQ: MYGN) has appointed Brian Donnelly as its new Chief Commercial Officer (CCO), effective May 1, 2025. Donnelly brings over 20 years of experience in healthcare, diagnostics, and medical technology, with a history of managing multi-billion-dollar P&Ls and driving growth through innovative strategies.
The appointment was announced by Sam Raha, incoming president and CEO, who highlighted Donnelly's strategic vision and operational excellence. Prior to joining Myriad, Donnelly held senior commercial and general management positions at Ancestry, Amazon, and Illumina, where he successfully drove business growth across global markets and product lines.
Myriad Genetics (NASDAQ: MYGN) ha nominato Brian Donnelly come nuovo Chief Commercial Officer (CCO), con effetto dal 1 maggio 2025. Donnelly porta con sé oltre 20 anni di esperienza nel settore sanitario, diagnostica e tecnologia medica, con una storia di gestione di P&L da miliardi di dollari e di promozione della crescita attraverso strategie innovative.
La nomina è stata annunciata da Sam Raha, prossimo presidente e CEO, che ha sottolineato la visione strategica e l'eccellenza operativa di Donnelly. Prima di unirsi a Myriad, Donnelly ha ricoperto posizioni di alto livello nel commercio e nella gestione generale presso Ancestry, Amazon e Illumina, dove ha guidato con successo la crescita aziendale nei mercati globali e nelle linee di prodotto.
Myriad Genetics (NASDAQ: MYGN) ha nombrado a Brian Donnelly como su nuevo Director Comercial (CCO), con efecto a partir del 1 de mayo de 2025. Donnelly aporta más de 20 años de experiencia en atención médica, diagnóstico y tecnología médica, con un historial de gestión de P&L de miles de millones de dólares y de impulso del crecimiento a través de estrategias innovadoras.
El nombramiento fue anunciado por Sam Raha, próximo presidente y CEO, quien destacó la visión estratégica y la excelencia operativa de Donnelly. Antes de unirse a Myriad, Donnelly ocupó puestos de alta dirección comercial y de gestión general en Ancestry, Amazon e Illumina, donde impulsó con éxito el crecimiento empresarial en mercados globales y líneas de productos.
Myriad Genetics (NASDAQ: MYGN)는 Brian Donnelly을 새로운 최고 상업 책임자(CCO)로 임명했으며, 이는 2025년 5월 1일부터 효력이 발생합니다. Donnelly는 의료, 진단 및 의료 기술 분야에서 20년 이상의 경험을 보유하고 있으며, 수십억 달러 규모의 P&L을 관리하고 혁신적인 전략을 통해 성장을 이끌어낸 경력을 가지고 있습니다.
이번 임명은 Sam Raha 차기 사장 겸 CEO에 의해 발표되었으며, Donnelly의 전략적 비전과 운영 우수성을 강조했습니다. Myriad에 합류하기 전, Donnelly는 Ancestry, Amazon, Illumina에서 고위 상업 및 일반 관리직을 역임하며 글로벌 시장과 제품 라인에서 비즈니스 성장을 성공적으로 이끌었습니다.
Myriad Genetics (NASDAQ: MYGN) a nommé Brian Donnelly en tant que nouveau Directeur Commercial (CCO), à compter du 1er mai 2025. Donnelly apporte plus de 20 ans d'expérience dans le secteur de la santé, du diagnostic et de la technologie médicale, avec un historique de gestion de P&L de plusieurs milliards de dollars et de stimulation de la croissance grâce à des stratégies innovantes.
La nomination a été annoncée par Sam Raha, futur président et CEO, qui a souligné la vision stratégique et l'excellence opérationnelle de Donnelly. Avant de rejoindre Myriad, Donnelly a occupé des postes de direction commerciale et de gestion générale chez Ancestry, Amazon et Illumina, où il a réussi à stimuler la croissance des affaires à l'échelle mondiale et dans les gammes de produits.
Myriad Genetics (NASDAQ: MYGN) hat Brian Donnelly zum neuen Chief Commercial Officer (CCO) ernannt, mit Wirkung zum 1. Mai 2025. Donnelly bringt über 20 Jahre Erfahrung im Gesundheitswesen, in der Diagnostik und Medizintechnologie mit, mit einer Geschichte in der Verwaltung von Milliarden-Dollar-P&L und der Förderung von Wachstum durch innovative Strategien.
Die Ernennung wurde von Sam Raha, dem kommenden Präsidenten und CEO, bekannt gegeben, der Donnellys strategische Vision und operative Exzellenz hervorhob. Vor seinem Eintritt bei Myriad hatte Donnelly leitende kommerzielle und allgemeine Managementpositionen bei Ancestry, Amazon und Illumina inne, wo er erfolgreich das Unternehmenswachstum in globalen Märkten und Produktlinien vorantrieb.
- Appointment of experienced executive with track record of managing multi-billion-dollar P&Ls
- Strategic hire with proven success in driving business growth across global markets
- Previous leadership experience at major companies (Ancestry, Amazon, Illumina)
- None.
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.
A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies.
“Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution,” said Sam Raha, incoming president and CEO of Myriad Genetics. “He will be a critical member of our leadership team and will play an instrumental role in scaling our business, accelerating product adoption, and driving sustained profitable growth.”
"I’m thrilled to join Myriad Genetics, which has such a deep commitment to advancing genetic insights and plays a critical role in empowering patients, physicians, and partners with the information needed to improve health outcomes,” said Donnelly. “I look forward to working alongside this talented team to expand our impact, foster innovation, and accelerate the company’s growth while staying true to Myriad’s mission of advancing health and well-being for all."
Prior to joining Myriad Genetics, Donnelly held senior commercial and general management roles at leading organizations such as Ancestry, Amazon, and Illumina, successfully driving business growth across global markets and product lines. His ability to align commercial efforts with organizational goals, enhance brand positioning, and deliver shareholder value makes him well-positioned to build on Myriad’s mission.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostics testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.
Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including that Mr. Donnelly will be a critical member of the company’s leadership team and will play an instrumental role in scaling the company’s business, accelerating product adoption, and driving sustained profitable growth. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Kate Schraml
(224) 875-4493
PR@myriad.com
FAQ
When will Brian Donnelly start as CCO at Myriad Genetics (MYGN)?
What is Brian Donnelly's professional background before joining MYGN?
Who announced Brian Donnelly's appointment at Myriad Genetics (MYGN)?
What will be Brian Donnelly's main responsibilities at MYGN?
